Mitogen-activated protein kinase pathway and Matrix metalloproteinase-9 (MAPK/MMP-9)

The Mitogen-activated protein kinase (MAPK) pathway and Matrix metalloproteinase-9 (MMP-9) constitute a major regulatory axis in cellular physiology and pathology. The MAPK signaling cascade, which includes the ERK, JNK, and p38 pathways, acts as a transducer for extracellular signals that trigger the expression of MMP-9 via transcription factors like AP-1 and NF-κB (PubMed: 28651541). MMP-9 is a gelatinase responsible for degrading the extracellular matrix (ECM), a process essential for physiological tissue remodeling but also exploited by cancer cells for invasion and metastasis (UniProt: P14780). In various cancers and inflammatory diseases, overactivation of the MAPK pathway leads to excessive MMP-9 production, facilitating basement membrane degradation and tumor spread. While MEK and BRAF inhibitors are clinically used to target the MAPK pathway, direct MMP-9 inhibitors have historically struggled in clinical development due to a lack of selectivity and the development of musculoskeletal syndrome (PubMed: 12195160).

Other names

MAPK signaling cascadeGelatinase B92 kDa type IV collagenaseMMP9MAPK-MMP9 axis

Inhibition of the MAPK signaling cascade (e.g., MEK or ERK inhibition) to downregulate downstream effectors, and direct inhibition of the proteolytic activity of Matrix metalloproteinase-9 to prevent extracellular matrix degradation.